Then what could be the consequences, and what are the potential answers for the food industry
The 2026 shift in treating them is the same one sweeping all of skincare: away from harsh, stripping protocols that inflame skin into producing more pigment, toward gentle, regenerative actives that repair while they fade
doi: 10.1016/j.cellin.2025.100257 192 XiaoHDuXTaoZJingNBaoSGaoWQet al
Treatment with GE2 was effective at reducing cytokine levels in the dorsal and ventral hippocampus, in rats fed a SD, but not WD
because rigorously controlled human safety data specific to the TB-500 fragment does not exist, its longer-term risk profile, including possible immune reactions, remains unknown Evidence snapshot: Evidence for TB-500 itself is preclinical, drawn mainly from cell-culture and animal studies (a 1999 rat wound-healing study and later rodent cardiac- and tendon-injury models), with a 2026 scoping review describing the musculoskeletal literature on thymosin beta-4 and TB-500 as sparse and largely preclinical
)
.jpg)
